期刊
PIGMENT CELL & MELANOMA RESEARCH
卷 22, 期 4, 页码 454-460出版社
WILEY
DOI: 10.1111/j.1755-148X.2009.00576.x
关键词
Met; melanocytes; Cdkn2a; transformation; progression
资金
- Melanoma Research Foundation
- James A. Schlipmann Melanoma Cancer Foundation
- Van Andel Research Institute
- Nevada Cancer Institute
- National Cancer Institute [R01CA121118]
P>While many genetic alterations have been identified in melanoma, the relevant molecular events that contribute to disease progression are poorly understood. Most primary human melanomas exhibit loss of expression of the CDKN2A locus in addition to activation of the canonical mitogen-activated protein kinase signaling pathway. In this study, we used a Cdkn2a-deficient mouse melanocyte cell line to screen for secondary genetic events in melanoma tumor progression. Upon investigation, intrachromosomal gene amplification of Met, a receptor tyrosine kinase implicated in melanoma progression, was identified in Cdkn2a-deficient tumors. RNA interference targeting Met in these tumor cells resulted in a significant delay in tumor growth in vivo compared with the control cells. MET expression is rarely detected in primary human melanoma but is frequently observed in metastatic disease. This study validates a role for Met activation in melanoma tumor progression in the context of Cdkn2a deficiency.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据